Efficacy and side effects of Type A botulinum toxin injection in patients with hemifacial spasm receiving treatment at the Botulinum toxin clinic, Buddhasothorn hospital
Article Sidebar
Main Article Content
Abstract
Background: Hemifacial spasm (HFS) is a condition characterized by involuntary facial movements on one side that cannot be controlled. Buddhasothorn Hospital has established a clinic for Type A botulinum toxin injections to treat hemifacial spasm for over 10 years. However, there has been no data collection regarding treatment efficacy, duration of effectiveness, and side effects following the injections.
Objectives: To study the effectiveness, duration of effect, and side effects following treatment of hemifacial spasm using Type A botulinum toxin injections.
Methods: This is a descriptive cross-sectional study conducted on the outpatients receiving medical treatment at the Department of Rehabilitation Medicine, Buddhasothorn Hospital, from May to June 2024. Data was collected through interviews and recorded in data collection forms. Data analysis was performed using descriptive statistics, including percentages and means.
Results: There are a total of 37 patients with hemifacial spasm, comprising 6 males and 31 females. The majority of patients responded well to treatment, with the response lasting more than 10 weeks. The treatment efficacy for most patients ranged from good to excellent. However, 21 patients experienced side effects from the medication, with the most common being eye irritation and dry eyes.
Conclusions: The use of botulinum toxin type A for treating patients with hemifacial spasm has been found to have effectiveness ranging from good to excellent. The duration of response tends to be longer than 10 weeks for most patients. Common side effects include dry eyes, eye irritation, or bruising at the injection site.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Tambasco N, Filidei M, Nigro P, Parnetti L, Simoni S. Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies. Toxins. 2021;13(12).
Wang A, Jankovic J. Hemifacial spasm: clinical findings and treatment. Muscle & nerve. 1998;21(12):1740-7.
Nurminen P, Marjamaa J, Niemelä M, Sairanen T. Incidence and prevalence of Hemifacial Spasm in Finland's largest hospital district. Journal of the Neurological Sciences. 2023;446:120587.
Anandan C, Jankovic J. Botulinum Toxin in Movement Disorders: An Update. 2021;13(1):42.
Jankovic J. An update on new and unique uses of botulinum toxin in movement disorders. Toxicon : official journal of the International Society on Toxinology. 2018;147:84-8.
Streitová H, Bareš M. Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years. Acta neurologica Belgica. 2014;114(4):285-91.
Sirimattayapant T. The study of efficacy of Botulinum toxin A in hemifacial spasm in Trang Hospital. J Prapokklao Hosp Clin Med Educ Cent. 2021;38:243-50.
Setthawatcharawanich S, Ovartlanporn S. Effective treatment of hemifacial spasm and blepharospasm with botulinum toxin type A in Songklanagarind Hospital. Journal of Health Science and Medical Research (JHSMR). 2007;25.
Nigam PK, Nigam A. Botulinum toxin. Indian journal of dermatology. 2010;55(1):8-14.
Hallett M. Explanation of timing of botulinum neurotoxin effects, onset and duration, and clinical ways of influencing them. Toxicon : official journal of the International Society on Toxinology. 2015;107(Pt A):64-7.
Poungvarin N, Nilanont Y, Prayoonwiwat N, Senanarong V. Hemifacial Spasm Treated with Botulinum Toxin Injection : A Ten-Year Experience at Siriraj Hospital. Siriraj Medical Journal. 2020;53(1):1-7.